The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
IntroductionPsoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with re...
Saved in:
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_0425efa1f7f34b929bd2f6ccd7239b0c | ||
042 | |a dc | ||
100 | 1 | 0 | |a Paulina Maravilla-Herrera |e author |
700 | 1 | 0 | |a María Merino |e author |
700 | 1 | 0 | |a Santiago Alfonso Zamora |e author |
700 | 1 | 0 | |a Jesús Balea Filgueiras |e author |
700 | 1 | 0 | |a José Manuel Carrascosa Carrillo |e author |
700 | 1 | 0 | |a Olga Delgado Sánchez |e author |
700 | 1 | 0 | |a Olga Delgado Sánchez |e author |
700 | 1 | 0 | |a Francisco Dolz Sinisterra |e author |
700 | 1 | 0 | |a Antonio García-Ruiz |e author |
700 | 1 | 0 | |a Pedro Herranz Pinto |e author |
700 | 1 | 0 | |a Antonio Manfredi |e author |
700 | 1 | 0 | |a José Martínez Olmos |e author |
700 | 1 | 0 | |a Paloma Morales de los Ríos Luna |e author |
700 | 1 | 0 | |a Lluís Puig |e author |
700 | 1 | 0 | |a Lluís Puig |e author |
700 | 1 | 0 | |a Sandra Ros |e author |
700 | 1 | 0 | |a Álvaro Hidalgo-Vega |e author |
700 | 1 | 0 | |a Álvaro Hidalgo-Vega |e author |
245 | 0 | 0 | |a The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain |
260 | |b Frontiers Media S.A., |c 2023-01-01T00:00:00Z. | ||
500 | |a 2296-2565 | ||
500 | |a 10.3389/fpubh.2023.1000776 | ||
520 | |a IntroductionPsoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with respect to the baseline PASI score, has traditionally been used as a therapeutic benchmark in clinical trials. Therapeutic advances have made PASI 90 or PASI 100 responses possible in most patients treated with some biologics. A greater response may generate social value beyond clinical outcomes that would benefit both patients and society.MethodsA 1-year economic model was applied to estimate the impact of having a PASI 75, PASI 90, or PASI 100 response in four areas of analysis (quality of life, activities of daily living, work productivity, and out-of-pocket expenditures) and the social value of having a PASI 90 or PASI 100 response in comparison with a PASI 75 response. A mixed-methods approach based on the scientific literature, a focus group with patient, and an advisory committee with psoriasis stakeholders was used. The model included three different scenarios: having a PASI 90 vs a PASI 75 response; a PASI 100 vs a PASI 90 response; and a PASI 100 vs a PASI 75 response. A sensitivity analysis was included.ResultsThe annual economic impact per patient with moderate-to-severe plaque psoriasis having a PASI 75 response was estimated at Ł 6,139, mainly related to labour productivity losses and quality of life reductions. Having a PASI 90 or a PASI 100 response would reduce this impact to €3,956 or €1,353, respectively. Accordingly, the social value of having a PASI 90 instead of a PASI 75 response was estimated at €2,183, and €4,786 with a PASI 100 response.DiscussionA PASI 90 or PASI 100 response would have a lower economic impact and a greater social value than a PASI 75 response for patients with moderate-to-severe plaque psoriasis. | ||
546 | |a EN | ||
690 | |a social return | ||
690 | |a socioeconomic impact | ||
690 | |a psoriasis | ||
690 | |a Psoriasis Area and Severity Index (PASI) | ||
690 | |a quality of life | ||
690 | |a out-of-pocket (OOP) expenses | ||
690 | |a Public aspects of medicine | ||
690 | |a RA1-1270 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Frontiers in Public Health, Vol 11 (2023) | |
787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fpubh.2023.1000776/full | |
787 | 0 | |n https://doaj.org/toc/2296-2565 | |
856 | 4 | 1 | |u https://doaj.org/article/0425efa1f7f34b929bd2f6ccd7239b0c |z Connect to this object online. |